NCT05702073View on ClinicalTrials.gov

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

PHASE3CompletedINTERVENTIONAL
Enrollment

423

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

June 11, 2024

Study Completion Date

June 11, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

INS068 injection

INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial

DRUG

Insulin Glargine

Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial

Trial Locations (1)

200032

Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY